Advocacy Clinical Trials Safety 
Veriheal
AUGUST 22, 2022
Clinical trials into cannabis’ potential as an opioid replacement are well underway in South Africa. Quite frankly, the clinical trials couldn’t have come at a better time. Grinspoon’s devotion to cannabis stems from his father Lester Grinspoon’s longtime advocacy efforts. .
NORML
JANUARY 4, 2019
Separate provisions in the bill exclude cannabidiol from the federal definition of marijuana, permit VA doctors to authorize medical cannabis access to qualified patients, and remove undue federal barriers to clinical trial research to better assess the safety and efficacy of medical cannabis.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MMJ Recs
JULY 9, 2024
of medical marijuana as a viable treatment option for certain conditions, including Multiple Sclerosis (MS), leading to increased advocacy for uniform regulations and broader accessibility. Some clinical trials have shown that cannabinoids, particularly THC and CBD, effectively reduce muscle spasticity and pain in MS patients.
Cannabis Law Report
OCTOBER 20, 2021
s NORML Coordinator Dale Gieringer, Delta-8 has undergone minimal testing in humans, “therefore, little is known about its long-term safety, its consumption at high dosages, or its medicinal effects.” Additionally, the advocacy group views Delta-8 THC as a Schedule I substance under federal law. According to Calif.’s
Cannabis Law Report
JANUARY 12, 2022
Through this collaboration, the NPA and Maya will offer both the education and the technology infrastructure needed to make this possible, ensuring accessibility and safety to all communities. “We We don’t believe safety and access are opposing polarities that must be constantly balanced. ABOUT THE NATIONAL PSYCHEDELICS ASSOCIATION.
MMJ Recs
NOVEMBER 30, 2023
While anecdotal evidence and individual success stories have sparked interest in using MMJ for seizure control, scientific research plays a crucial role in establishing its safety and efficacy. Clinical trials and studies are underway to examine the potential benefits and risks of MMJ as a treatment option for epilepsy.
Cannabis Law Report
DECEMBER 3, 2021
We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We
Expert insights. Personalized for you.
116 
Let's personalize your content